PM pushes back after Trump’s threats to leave alliance and says European members must do more in light of Iran war Keir Starmer has said it is in the best interests of the US to stay in Nato and that Europe must do more to support the alliance in light of the war in Iran. The British prime minister, speaking at the end of a multi-stop trip around the Gulf to discuss the tentative ceasefire and opt...
PM pushes back after Trump’s threats to leave alliance and says European members must do more in light of Iran war Keir Starmer has said it is in the best interests of the US to stay in Nato and that Europe must do more to support the alliance in light of the war in Iran. The British prime minister, speaking at the end of a multi-stop trip around the Gulf to discuss the tentative ceasefire and options to fully reopen the commercially vital strait of Hormuz, pushed back against Donald Trump’s threats to leave the defence alliance . Continue reading...
APP's push into self-serve e-commerce ads could widen its advertiser base, with AI tools and strong onboarding conversions signaling a potential new growth driver.
APP's push into self-serve e-commerce ads could widen its advertiser base, with AI tools and strong onboarding conversions signaling a potential new growth driver.
Is Nike done? That's the question Jim Cramer posed Friday morning on CNBC after what he called a "very damning" analyst downgrade. "I've been trying to figure out whether it is a mistake or whether we can give [CEO Elliott Hill] till October," Jim said later on Morning Meeting for Club members. October is important because it will mark the second anniversary of Hill assuming the helm at Nike. Sinc...
Is Nike done? That's the question Jim Cramer posed Friday morning on CNBC after what he called a "very damning" analyst downgrade. "I've been trying to figure out whether it is a mistake or whether we can give [CEO Elliott Hill] till October," Jim said later on Morning Meeting for Club members. October is important because it will mark the second anniversary of Hill assuming the helm at Nike. Since taking over as CEO, Hill has launched a turnaround strategy called "Win Now." It focuses on getting Nike back to its revered brand status by prioritizing the love of sport, driving innovation, repairing relationships with retail partners, and restructuring leadership. "It's a very hard business," Jim acknowledged, but he said he's inclined to stay with the stock for now. NKE YTD mountain Nike's year-to-date stock performance. Shares of Nike lost another 3% on Friday, trading in the low $40s, after Piper Sandler downgraded Nike to a hold-equivalent rating from buy and cut its price target to $50 a share from $60. Piper analysts cited concerns about Hill's leadership appointments, many of whom have worked at Nike for decades. "We worry if the correct execution of the turnaround requires more outside perspective as opposed to NKE veterans," the analysts wrote. Piper also expressed worries that athleisure was becoming "too saturated," and that Nike is "still overly dependent" on the success of its classic brands, which include Air Force 1, Air Jordan, and Dunk. In further proof that Hill's turnaround is taking and will continue to take longer than expected, Nike on March 31 reported flat revenue in its fiscal 2026 third quarter, with earnings per share down 35% year over year. Guidance for fiscal Q4 was also disappointing. Analysts don't expect Nike to return to annual sales growth until the February 2027 quarter. In response, the stock experienced a 15% post-earnings slide on April 1 and has only been higher in two sessions since. At the time, several Wall Street firms, incl...
May ICE NY cocoa (CCK26 ) today is up +68 (+2.15%), and May ICE London cocoa #7 (CAK26 ) is up +49 (+2.07%). Cocoa prices are moving higher today as a weak dollar ($DXY ) has prompted short covering in cocoa futures. An excessively short position by funds in London...
May ICE NY cocoa (CCK26 ) today is up +68 (+2.15%), and May ICE London cocoa #7 (CAK26 ) is up +49 (+2.07%). Cocoa prices are moving higher today as a weak dollar ($DXY ) has prompted short covering in cocoa futures. An excessively short position by funds in London...
The AI chip rally is proving something important this Friday afternoon: the opportunity in artificial intelligence silicon is wide enough to reward very different business models simultaneously. Advanced Micro Devices (NASDAQ:AMD) stock is up 4% today, moving from $236.64 to $246, while Broadcom (NASDAQ:AVGO) stock is climbing 5%, rising from $354.91 to $373. What makes ... AMD Gains 4%, Broadcom ...
The AI chip rally is proving something important this Friday afternoon: the opportunity in artificial intelligence silicon is wide enough to reward very different business models simultaneously. Advanced Micro Devices (NASDAQ:AMD) stock is up 4% today, moving from $236.64 to $246, while Broadcom (NASDAQ:AVGO) stock is climbing 5%, rising from $354.91 to $373. What makes ... AMD Gains 4%, Broadcom Climbs 5%: The AI Chip Rally Has Two Very Different Winners Today
In this article RVMD Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:19 02:19 What to know about Revolution Medicines' pancreatic cancer pill testing Money Movers Revolution Medicines could be on the cusp of a breakthrough. The company expects to soon release results from a Phase 3 trial of its experimental drug that could become the first targeted treatment for pancreatic cancer...
In this article RVMD Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:19 02:19 What to know about Revolution Medicines' pancreatic cancer pill testing Money Movers Revolution Medicines could be on the cusp of a breakthrough. The company expects to soon release results from a Phase 3 trial of its experimental drug that could become the first targeted treatment for pancreatic cancer, the deadliest of the major cancers. Just 13% of people with pancreatic cancer live five years after they're diagnosed, a number that hasn't changed much despite the outlook for other cancers improving thanks to new drugs like immunotherapy. The possibility of a new treatment has buoyed RevMed's stock by nearly 185% over the last year and made it a prime acquisition target. "This is incredibly important," said RBC Capital Markets analyst Leonid Timashev. "We've had physicians describe this as potentially the biggest breakthrough in pancreatic cancer ever." RevMed came into the spotlight this week when former Sen. Ben Sasse told The New York Times he's taking the company's drug, daraxonrasib. Sasse late last year announced he was diagnosed with Stage 4 pancreatic cancer and given three-to-four months to live. Sen. Ben Sasse (R-NE) speaks during Attorney General nominee Merrick Garland's confirmation hearing before the Senate Judiciary Committee, Washington, DC, February 22, 2021. Al Drago | Pool | Reuters Sasse told the Times that his tumors have shrunk by 76% since he started the treatment, but he called it a "nasty drug" that causes "crazy" side effects like a rash. Sasse's bloody, peeling face prompted the interviewer to tell Sasse he looks "terrible." RevMed's daily pill broadly targets RAS mutations, which drive tumor growth and are found in about 90% of pancreatic cancer cases. Timashev describes RevMed's drug as striking at the heart of what makes the cancer go. That's both a benefit and a liability. RAS proteins are all over the body, especially in the skin. RevMed'...
Larina Marina/iStock via Getty Images I last wrote about Safe Bulkers, Inc. ( SB ) in September. At the time, I described the company as a "calmer, cleaner ship" than the one I had previously covered in 2021. I argued that its modernized, compliance-ready dry bulk fleet and deep discount to NAV formed an attractive opportunity. Since then, SB stock has surged 43% and has almost doubled over the pa...
Larina Marina/iStock via Getty Images I last wrote about Safe Bulkers, Inc. ( SB ) in September. At the time, I described the company as a "calmer, cleaner ship" than the one I had previously covered in 2021. I argued that its modernized, compliance-ready dry bulk fleet and deep discount to NAV formed an attractive opportunity. Since then, SB stock has surged 43% and has almost doubled over the past 12 months. SB's Share Price Chart (Seeking Alpha) The rally makes sense, as the dry-bulk market has improved at a similar pace. Shipping looks quite attractive today, in general, as vessels are becoming increasingly critical for supply chains (containerships), and food and energy security (dry bulk and tankers). Indeed, the Baltic Dry Index, in particular, has surged, and investors have chased almost anything with leverage to freight. Safe Bulkers has been along for the ride, and while I still view it as one of the best-managed companies in the space, I don't think future gains will be as easy, and so I maintain a neutral view. The Story Is As Solid As It Gets Safe Bulkers hasn't stopped modernizing its fleet, which, together with the surge in rates, has helped the company capitalize on the dry bulk rally. The company ended Q4 with a 45-vessel fleet of 4.6 million deadweight tons. The average age of its vessels was a relatively young 10.5 years. And considering that 12 of its vessels were built from 2022 onward and met IMO GHG Phase 3 and NOx Tier III standards, which matter to charterers, I am not surprised that the company has the means to capture the dry bulk rally quite easily. Today, the company also has eight Kamsarmax newbuilds on order , including two methanol dual-fuel ships. Four are scheduled for delivery this year, with the remainder arriving slowly through 2029. As long as Safe Bulkers maintains a young, fuel-flexible fleet, it should have both a commercial advantage and a greater margin of safety than other players with older fleets. At the same time, I thi...